BIODESIX INC: directors' dealings · United States · SEC (Form 4)

About BIODESIX INC

Biodesix, Inc. (ticker BDSX) is a U.S.-based precision diagnostics company listed on the NASDAQ in the United States, with a focused franchise in lung disease and, more specifically, thoracic oncology. Founded in 2006 and headquartered in Louisville, Colorado, Biodesix has built a niche position around clinical decision support in lung cancer and pulmonary nodule management. Its corporate headquarters and primary laboratory are located at 919 W Dillon Road, Louisville, CO 80027. The company’s business model is centered on two complementary pillars. First, Biodesix commercializes proprietary diagnostic tests, notably under the Nodify Lung and IQLung brands. Nodify Lung is designed to help clinicians assess the malignancy risk of a lung nodule using blood-based biomarkers, supporting earlier and more informed care pathways. IQLung is a treatment-guidance portfolio for patients with non-small cell lung cancer, combining tumor profiling and immune profiling tools. Second, the company provides development services to biopharmaceutical, life sciences, and research customers, leveraging its scientific, technical, and operational capabilities to support diagnostic and therapeutic development programs. From a competitive standpoint, Biodesix operates in a highly specialized but attractive diagnostics market where clinical utility, reimbursement, turnaround time, and integration into physician workflows are critical. The company emphasizes clinically validated tests and a number of Medicare-covered offerings, which supports adoption in a market where evidence and reimbursement are decisive. Its differentiation is rooted in deep expertise in lung disease rather than in a broad, generalist diagnostics platform. Geographically, the business is primarily U.S.-focused, consistent with its headquarters, commercial footprint, and reimbursement-driven model. Recent company communications indicate improving momentum in 2025, with revenue growth supported by both diagnostic testing and development services. Biodesix has also highlighted new clinical and economic data supporting Nodify Lung, alongside a Thermo Fisher Scientific recognition as a Center of Excellence for NGS diagnostics, which helps reinforce the credibility of its technology platform. For French-speaking investors, Biodesix is best viewed as a specialized healthcare stock listed on the NASDAQ, with growth potential tied to execution, reimbursement dynamics, and broader adoption of its lung cancer diagnostics portfolio.